{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:55:06Z","timestamp":1791384906562,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12325-021-01905-5","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T12:31:28Z","timestamp":1631536288000},"page":"5317-5332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations"],"prefix":"10.1007","volume":"38","author":[{"given":"Emilie","family":"Henin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Laveille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-9380","authenticated-orcid":false,"given":"Giovanni","family":"Piotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"issue":"s1","key":"1905_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ajt.15672","volume":"20","author":"A Hart","year":"2020","unstructured":"Hart A, Smith JM, Skeans MA, et al. OPTN\/SRTR 2018 annual data report: kidney. Am J Transplant. 2020;20(s1):20\u2013130. https:\/\/doi.org\/10.1111\/ajt.15672.","journal-title":"Am J Transplant"},{"issue":"6","key":"1905_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.chembiol.2010.06.002","volume":"17","author":"TU Mayer","year":"2010","unstructured":"Mayer TU, Marx A. Five molecules we would take to a remote Island. Chem Biol. 2010;17(6):556\u201360. https:\/\/doi.org\/10.1016\/j.chembiol.2010.06.002.","journal-title":"Chem Biol"},{"issue":"3","key":"1905_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, Van Gelder T, \u00c5sberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307. https:\/\/doi.org\/10.1097\/FTD.0000000000000640.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"1905_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353. https:\/\/doi.org\/10.2165\/00003088-200443100-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1905_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40620-016-0316-3","volume":"30","author":"G Piotti","year":"2017","unstructured":"Piotti G, Cremaschi E, Maggiore U. Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. J Nephrol. 2017;30(1):53\u201361. https:\/\/doi.org\/10.1007\/s40620-016-0316-3.","journal-title":"J Nephrol"},{"issue":"6","key":"1905_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/TP.0b013e3181d62f1b","volume":"89","author":"JR Chapman","year":"2010","unstructured":"Chapman JR. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation. 2010;89(6):644\u20135. https:\/\/doi.org\/10.1097\/TP.0b013e3181d62f1b.","journal-title":"Transplantation"},{"issue":"10","key":"1905_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40262-015-0282-2","volume":"54","author":"CE Staatz","year":"2015","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clin Pharmacokinet. 2015;54(10):993\u20131025. https:\/\/doi.org\/10.1007\/s40262-015-0282-2.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1905_CR8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/ndt\/16.9.1905","volume":"16","author":"C Staatz","year":"2001","unstructured":"Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16(9):1905\u20139. https:\/\/doi.org\/10.1093\/ndt\/16.9.1905.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1905_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/FTD.0b013e3181a8f02a","volume":"31","author":"AM Borobia","year":"2009","unstructured":"Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit. 2009;31(4):436\u201342. https:\/\/doi.org\/10.1097\/FTD.0b013e3181a8f02a.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"1905_CR10","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1097\/TP.0000000000000149","volume":"97","author":"KR Richards","year":"2014","unstructured":"Richards KR, Hager D, Muth B, Astor BC, Kaufman D, Djamali A. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. Transplantation. 2014;97(10):986\u201391. https:\/\/doi.org\/10.1097\/TP.0000000000000149.","journal-title":"Transplantation"},{"issue":"6","key":"1905_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/clpt.2010.17","volume":"87","author":"E Thervet","year":"2010","unstructured":"Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721\u20136. https:\/\/doi.org\/10.1038\/clpt.2010.17.","journal-title":"Clin Pharmacol Ther"},{"key":"1905_CR12","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/ajt.13691","volume":"16","author":"N Shuker","year":"2016","unstructured":"Shuker N, Bouamar R, van Schaik RHN. A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body- weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2016;16:2085\u201396. https:\/\/doi.org\/10.1111\/ajt.13691.","journal-title":"Am J Transplant"},{"issue":"11","key":"1905_CR13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","volume":"55","author":"E Brooks","year":"2016","unstructured":"Brooks E, Tett SE, Isbel NM, Staatz CE. Population pharmacokinetic modelling and bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2016;55(11):1295\u2013335. https:\/\/doi.org\/10.1007\/s40262-016-0396-1.","journal-title":"Clin Pharmacokinet"},{"key":"1905_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00922-x","volume-title":"Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Springer International; 2020. https:\/\/doi.org\/10.1007\/s40262-020-00922-x."},{"key":"1905_CR15","unstructured":"Holm P. Meltdose Technology by the US Patent and Trademark Office. US7217431. 2007."},{"issue":"5","key":"1905_CR16","first-page":"B1034","volume":"13","author":"V Nigro","year":"2013","unstructured":"Nigro V, Glicklich A, Weinberg J. Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 h: a scintigraphic and pharmacokinetic evaluation. Am J Transplants. 2013;13(5):B1034.","journal-title":"Am J Transplants"},{"issue":"12","key":"1905_CR17","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1586\/1744666X.2014.983903","volume":"10","author":"JM Griny\u00f3","year":"2014","unstructured":"Griny\u00f3 JM, Petruzzelli S. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Rev Clin Immunol. 2014;10(12):1567\u201379. https:\/\/doi.org\/10.1586\/1744666X.2014.983903.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1905_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/TP.0b013e3182962cc1","volume":"96","author":"AO Gaber","year":"2013","unstructured":"Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation. 2013;96(2):191\u20137. https:\/\/doi.org\/10.1097\/TP.0b013e3182962cc1.","journal-title":"Transplantation"},{"key":"1905_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/lt.23844","volume":"20","author":"RR Alloway","year":"2014","unstructured":"Alloway RR. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transplant. 2014;20:564\u201375. https:\/\/doi.org\/10.1002\/lt.23844.","journal-title":"Liver Transplant"},{"issue":"2","key":"1905_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/ajt.13935","volume":"17","author":"S Tremblay","year":"2017","unstructured":"Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of All FK-506 (Tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm. Three-period crossover study. Am J Transplant. 2017;17(2):432\u201342. https:\/\/doi.org\/10.1111\/ajt.13935.","journal-title":"Am J Transplant"},{"issue":"3","key":"1905_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","volume":"71","author":"J Trofe-Clark","year":"2018","unstructured":"Trofe-Clark J, Brennan DC, West-Thielke P, et al. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients. Am J Kidney Dis. 2018;71(3):315\u201326. https:\/\/doi.org\/10.1053\/j.ajkd.2017.07.018.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1905_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12325-018-0855-1","volume":"36","author":"N Kamar","year":"2019","unstructured":"Kamar N, Cassuto E, Piotti G, et al. Pharmacokinetics of prolonged-release once-daily formulations of tacrolimus in de novo kidney transplant recipients: a randomized, parallel-group, open-label. Multicenter study. Adv Ther. 2019;36(2):462\u201377. https:\/\/doi.org\/10.1007\/s12325-018-0855-1.","journal-title":"Adv Ther"},{"key":"1905_CR23","doi-asserted-by":"publisher","unstructured":"Envarsus Summary of Product Characteristics. Annex I. https:\/\/doi.org\/10.2307\/j.ctvdf0dxq.12. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abecma-epar-product-information_en.pdf. Accessed 14 May 2021.","DOI":"10.2307\/j.ctvdf0dxq.12"},{"key":"1905_CR24","unstructured":"Envarsus Product Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206406s007lbl.pdf. Accessed 14 May 21."},{"issue":"12","key":"1905_CR25","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40262-017-0533-5","volume":"56","author":"JB Woillard","year":"2017","unstructured":"Woillard JB, Debord J, Monchaud C, Saint-Marcoux F, Marquet P. Population pharmacokinetics and bayesian estimators for refined dose adjustment of a new tacrolimus formulation in kidney and liver transplant patients. Clin Pharmacokinet. 2017;56(12):1491\u20138. https:\/\/doi.org\/10.1007\/s40262-017-0533-5.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1905_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"1905_CR27","unstructured":"Bauer RJ, Boeckmann AJ. III. NONMEM Installation NM7.3. 2013; (November)."},{"issue":"2","key":"1905_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a perl module for NONMEM related programming. Comput Methods Prog Biomed. 2004;75(2):85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Prog Biomed"},{"key":"1905_CR29","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna AU https:\/\/www.Rorg\/. The R Project for Statistical Computing. http:\/\/www.R-Project.Org\/. 2017."},{"issue":"5","key":"1905_CR30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/ajt.12191","volume":"13","author":"R Bouamar","year":"2013","unstructured":"Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. Am J Transplant. 2013;13(5):1253\u201361. https:\/\/doi.org\/10.1111\/ajt.12191.","journal-title":"Am J Transplant"},{"issue":"10","key":"1905_CR31","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","volume":"99","author":"E St\u00f8rset","year":"2015","unstructured":"St\u00f8rset E, \u00c5sberg A, Skauby M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective. Randomized Study. Transplantation. 2015;99(10):2158\u201366. https:\/\/doi.org\/10.1097\/TP.0000000000000708.","journal-title":"Transplantation"},{"issue":"12","key":"1905_CR32","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.clinthera.2010.11.010","volume":"32","author":"DRJ Kuypers","year":"2010","unstructured":"Kuypers DRJ, de Jonge H, Naesens M, Vanrenterghem Y. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther. 2010;32(12):2012\u201323. https:\/\/doi.org\/10.1016\/j.clinthera.2010.11.010.","journal-title":"Clin Ther"},{"issue":"5","key":"1905_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00228-017-2204-8","volume":"73","author":"MA Sikma","year":"2017","unstructured":"Sikma MA, Hunault CC, van de Graaf EA, et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. Eur J Clin Pharmacol. 2017;73(5):573\u201380. https:\/\/doi.org\/10.1007\/s00228-017-2204-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1905_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/fcp.12432","volume":"33","author":"F Lemaitre","year":"2019","unstructured":"Lemaitre F, Lorcy N, Tron C, et al. Tacrolimus overexposure in kidney transplant recipients during the first post-operative week: caution is required in older patients. Fundam Clin Pharmacol. 2019;33(3):347\u201354. https:\/\/doi.org\/10.1111\/fcp.12432.","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"1905_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"T Vanhove","year":"2016","unstructured":"Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48(1):88\u2013112. https:\/\/doi.org\/10.3109\/03602532.2016.1151037.","journal-title":"Drug Metab Rev"},{"issue":"12","key":"1905_CR36","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1111\/bcp.14110","volume":"85","author":"TM Nanga","year":"2019","unstructured":"Nanga TM, Doan TTP, Marquet P, Musuamba FT. Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: a model-based meta-analysis approach. Br J Clin Pharmacol. 2019;85(12):2793\u2013823. https:\/\/doi.org\/10.1111\/bcp.14110.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1905_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.5414\/CPP42701","volume":"42","author":"NL Dirks","year":"2004","unstructured":"Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2004;42(12):701\u201318. https:\/\/doi.org\/10.5414\/CPP42701.","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01905-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T09:06:47Z","timestamp":1632820007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01905-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1905"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01905-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,12]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}